MDLinxWhen the Tumor Genome Changes: Recognizing Molecular Evolution During Treatment

🎓 Expert Commentary / Peer Perspective

Cancer treatment can alter tumor composition by eliminating sensitive clones while allowing resistant populations to expand. This review describes how comprehensive genomic profiling establishes a baseline molecular understanding of a tumor, while serial circulating tumor DNA monitoring may help identify evolving resistance mechanisms during treatment. The article uses metastatic colorectal cancer as an example, highlighting how serial ctDNA can detect acquired RAS mutations associated with anti-EGFR resistance and may aid assessment of rechallenge strategies. The discussion is educational and does not present new clinical outcomes data.

Clinical Considerations

• Comprehensive genomic profiling (CGP) helps identify actionable alterations and truncal genomic drivers at diagnosis.
• Serial ctDNA monitoring may reveal emerging resistance mechanisms and molecular progression over time.
• In metastatic colorectal cancer, acquired RAS mutations are a recognized mechanism of anti-EGFR resistance.
• Serial ctDNA may identify resistant subclones before overt radiographic progression becomes apparent.
• Molecular findings should be interpreted alongside imaging, tumor markers, clinical status, and treatment goals.
• The article describes current clinical concepts and examples rather than reporting prospective validation of a specific monitoring strategy.

Practice Applications

• Consider CGP as a foundation for identifying actionable biomarkers and therapeutic targets.
• Integrate ctDNA results with radiographic findings and clinical assessment rather than viewing molecular results in isolation.
• Monitor for emerging resistance mechanisms when disease progression is suspected during targeted therapy.
• Review whether serial molecular monitoring could provide additional information beyond baseline genomic testing.
• Interpret molecular evolution findings within the context of the patient’s overall treatment strategy and disease course.